企業レポート

バイエル:製薬企業分析レポート

Bayer: Pipeline * Products * Performance * Potential

発行 Espicom Business Intelligence 商品コード 25000
出版日 ページ情報 英文 136 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
バイエル:製薬企業分析レポート Bayer: Pipeline * Products * Performance * Potential
出版日: 2010年11月17日 ページ情報: 英文 136 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

製薬、医療機器市場に関する調査会社として権威のある情報を提供するEspicom Business Intelligence(本社:英国)では、Bayer社の業務分析を行った報告書"Bayer - Prospects to 2010"を発行いたしました。

当報告書では、Bayer社の企業戦略、製品ポートフォリオ、財務実績や、2000年から2010年までの売上データなどを概略下記の構成でお届けいたします。

エグゼクティブサマリー

  • イントロダクション
  • 2005年の財務実績
    • 売上
    • 収益
    • 支出
    • 事業部業績
  • 企業戦略
    • M&A
    • 主な提携
    • 生産
    • 地域別業績
    • 従業員
  • 製品/R&D概要
    • 主要製品
    • R&D戦略
    • R&Dパイプライン概要
    • 売上予測
  • 結論

製品ポートフォリオ/R&D

  • 生物製剤
  • 感染症
  • 心血管疾患
  • 代謝性疾患
  • 中枢神経系
  • 呼吸器
  • リウマチ
  • 骨疾患

付録

  • 財務実績
  • 主な提携
  • インフラ
    • 研究開発施設
    • 生産施設
  • 関連会社/ジョイント・ベンチャー
  • 製品インデックス
目次
Product Code: 118

Abstract

Bayer is a global enterprise, headquartered in Germany, with core competencies in the fields of healthcare, nutrition and high-tech materials. This report provides a full review of the company' s activities together with sales forecasts for key products to 2010.

Bayer is a global enterprise, headquartered in Germany, with core competencies in the fields of healthcare, nutrition and high-tech materials. It currently ranks 15th among research-based pharmaceutical companies in terms of pharma sales and annually invests about 7.1 per cent of its total sales in research and development, ranking 74th compared to other pharmaceutical companies. Oncology and cardiovascular risk management, including diabetes, are the main areas of Bayer' s future strategic focus within pharmaceuticals.

Current Growth Drivers

With successful life-cycle management, the established products Levitra, Kogenate, Trasylol and Avalox continue to drive sales.

Key Late-Phase Products Reaching the Market Place

Nexavar was launched for renal cell carcinoma in the US in December 2005, and an EU launch is expected in the second half of 2006. A Phase III trial in hepatocellular carcinoma started in March 2005, is now completed.

Key Late-Stage Products

BAY 59-7939, an oral, direct inhibitor of Factor Xa, is currently in Phase III development for venous thromboembolism (VTE) prevention after major orthopaedic surgery has been initiated. The product is on schedule for regulatory filing in late 2007.

Table of Contents

Principal Operating Results

Breaking News

Latest Results

Executive Summary

  • Introduction
  • Financial Performance 2005
    • Sales
    • Income
      • Sales, Costs and Operating Income
    • Expenditure
      • Capital Expenditure
      • Capital Expenditure By Business Area
      • Capital Expenditure By Business Area, 2005
      • Capital Expenditure By Geographic Area
      • Capital Expenditure By Geographic Area, 2005
      • R&D Expenditure
      • Research and Development Expenditure By Business Area
      • Research and Development Expenditure By Business Area, 2005
      • Research and Development By Geographic Area
      • Research and Development By Geographic Area, 2005
    • Divisional Performance
      • Sales By Business Area
      • Sales By Business Area, 2005
      • Operating Income By Business Area
  • Company Strategy
    • Mergers, Acquisitions and Divestitures
    • Key Agreements
    • Production
    • Geographical Breakdown
      • Sales By Destination
      • Sales By Destination, 2005
      • Sales By Origin
      • Sales By Origin, 2005
      • Operating Income By Geographical Area
      • Operating Income By Geographical Area, 2005
    • Employees
      • Employees By Business Area
      • Employees By Geographical Area
  • Product/R&D Overview
    • Key Products
      • Recent Product Launches
      • Recent Product Approvals
    • R&D Strategy
      • Key R&D projects
    • R&D Pipeline Overview
    • Sales Forecast
      • Sales of Current Major Products (2000A-2010E)
  • Other Factors Affecting the Bottom Line
  • Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

  • Major Products, Therapeutic Areas and Sales
  • Sales By Major Product, 2005
  • Biological Products - Products
    • Major Product Launches
    • Kogenate/Kogenate FS
      • Sales
      • Key Markets/Indications/Formulations
      • Further Development
      • Competitor Products
      • Sales Forecast
    • Kogenate Sales (2000A-2010E)
      • Clinical Trial Results - Prophylaxis
    • Trasylol
      • Sales
      • Key Markets/Indications/Formulations
      • Further Development
      • Safety Studies
  • Biological Products - R&D
  • Biological Products - Summary
    • Growth Potential
    • Limiting Factors
  • Infectious Diseases - Products
    • Major Launched Products
    • Avelox/Avalox
      • Mode of Action
      • Sales
      • Key Markets/Indications/Formulations
      • Further Development
      • Generic Competition
      • Sales Forecast
    • Avalox Sales (2000A-2010E)
      • Clinical Trial Results
    • Cipro/Ciprobay
      • Sales
      • Key Markets/Indications/Formulations
      • Lawsuit/Generic Competition
      • Sales Forecast
    • Cipro/Ciprobay Sales (2000A-2010E)
    • Others
  • Infectious Diseases - R&D
  • Infectious Diseases - Summary
  • Cardiovascular - Products
    • Major Launched Products
    • Adalat
      • Sales
      • Key Markets/Indications/Formulations
      • Generic Competition/Lawsuits/Patents
      • Sales Forecast
    • Adalat Sales (2000A-2010E)
      • Clinical Trial Results
    • Kinzalmono
      • Key Markets/Indications/Formulations
    • Levitra/Vivanza
      • Sales
      • Key Markets/Indications/Formulations
      • Further Development
      • Competitor Products
      • Generic Competition/Lawsuits
      • Safety Issues
      • Clinical Trial Results
    • Others
      • Nisoldipine for Echocardiography
  • Cardiovascular - R&D
    • Alfimeprase
      • Development Status
      • Clinical Trial Results
    • BAY 44-2041
    • BAY 58-2667
    • BAY 59-3394
    • BAY 59-7939
      • Clinical Trial Results
    • BAY 60-5521
    • BAY 63-2521
    • BAY 68-4986
    • BAY 73-7977
  • Cardiovascular - Summary
    • Growth Potential
    • Limiting Factors
  • Metabolic Disorders - Products
    • Major Launched Products
    • Diastabol/Glyset
      • Key Markets/Indications
    • Glucobay/Precose
      • Mode of Action
      • Sales
      • Key Markets/Indications/Formulations
      • Further Development
      • Competitor Products
      • Sales Forecast
    • Glucobay/Precose Sales (2000A-2010E)
  • Metabolic Disorders - R&D
  • Metabolic Disorders - Summary
  • Oncology - Products
    • Nexavar (sorafenib; BAY 43-9006)
      • Mode of Action
      • Key Markets/Indications
      • Further Development
      • Clinical Trial Results in Renal Cell Carcinoma
    • Viadur
      • Key Markets/Indications/Formulations
  • Oncology - R&D
    • BAY 50-4798
    • BAY 57-9352
    • BAY 73-4506
  • Oncology - Summary
    • Growth Potential
    • Limiting Factors
  • Central Nervous System - Products
    • Sativex (BAY 38-7271)
      • Markets/Indications
      • Further Development
      • Compassionate Access
      • Clinical Trial Results - Spasticity in MS
      • Clinical Trial Results - Neuropathic Pain
      • Clinical Trial Results - Rheumatoid Arthritis
      • Clinical Trial Results - Cancer Pain
    • Other CNS Products
  • Central Nervous System - Summary
  • Respiratory - Summary
  • Rheumatoid Diseases - Summary
  • Bone Disorders - R&D
    • BAY 39-9624
  • Bone Disorders - Summary

APPENDIX 1 - FINANCI AL PERFORMANCE

  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity

APPENDIX 2 - KEY AGREEMENTS

  • Actimis Pharmaceuticals
    • 28th April 2005
  • Asklepios Biopharmaceutical Inc
    • 18th May 2005
  • Bausch & Lomb
    • 7th January 2005
  • Boehringer Ingelheim
    • 15th August 2002
  • Bristol-Myers-Squibb
    • 10th December 2004
  • CuraGen Corporation
    • 16th January 2001
    • 20th June 2001
    • 30th January 2002
    • 18th September 2002
    • 26th October 2004
    • 20th December 2005
  • deCODE genetics
    • 16th November 2003
    • 19th October 2004
  • First Horizon Pharmaceutical Corporation
    • 6th March 2002
    • 6th January 2006
  • GlaxoSmithKline
    • 22nd July 1997
    • 18th February 2002
    • 10th January 2005
    • 3rd January 2006
  • GW Pharmaceuticals plc
    • 21st May 2003
    • 6th November 2003
    • 11th May 2005
  • Johnson & Johnson
    • 5th April 2000
    • 26th October 2005
  • Medicines for Malaria Venture (MMV)
    • 7th May 2002
  • Memory Pharmaceuticals Inc
    • 11th September 2001
  • Millennium Pharmaceuticals Inc
    • 23rd September 1998
    • 11th November 1998
    • 31st October 2003
  • Nektar Therapeutics Corporation
    • 25th January 2005
  • Nippon Shinyaku
    • 24th April 2006
  • Novartis Pharma GmbH
    • 17th December 2004
  • Nuvelo Inc
    • 5th January 2006
  • Onyx Pharmaceuticals Inc
    • February 1994
    • 1st February 1999
  • Ranbaxy Laboratories Limited
    • 8th September 1999
  • Remedyne Corporation
    • 4th March 2002
  • Schering-Plough
    • 1st October 2004
  • Shionogi
    • 17th October 2005
  • Ventiv Health Inc
    • 14th February 2005
  • World Heart Federation
    • 4th September 2005
  • Zilip-Pharma
    • 22nd November 2004

APPENDIX 3 - INFRASTRUCTURE

  • Research and Development Facilities
    • The SNP Consortium
  • Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

  • Subsidiaries
  • Joint-Venture Companies

APPENDIX 5 - PRODUCT INDEX

Back to Top